Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Bot, Adrian ^a   Qiu, Zhiyong ^a   Wong, Raymond ^a   Obrocea, Mihail ^a   Smith, Kent A ^a  

^a MannKind Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROGRAMMED DEATH 1 RECEPTOR; TOLL LIKE RECEPTOR; APOPTOSIS REGULATORY PROTEIN;

ANTIGEN SPECIFICITY; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; DNA IMMUNIZATION; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SECONDARY IMMUNE RESPONSE; VIRUS INFECTION; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CROSS PRESENTATION; IMMUNITY; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KINETICS; METHODOLOGY; VACCINATION;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; HUMANS; IMMUNITY; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; KINETICS; MODELS, IMMUNOLOGICAL; VACCINATION; VACCINES, DNA;

EID: 78649937720     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-132     Document Type: Review

References (66)

1. Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 2000, 18:1436-1447. 10.1016/S0264-410X(99)00434-X, 10618541.
2. Schiller JT, Lowy DR. Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol 2010, 64:23-41. 10.1146/annurev.micro.112408.134019, 20420520.
3. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2010, 363:943-53. 10.1056/NEJMoa0908806, 20818904.
4. Boon T, Szikora JP, De Plaen E, Wölfel T, Van Pel A. Cloning and characterization of genes coding for tum- transplantation antigens. J Autoimmun 1989, 2:s109-114.
5. Morse MA, Whelan M. A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther 2010, 12:11-13.
6. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: Vaccines for solid tumours. The Lancet Oncology 2004, 5:681-9. 10.1016/S1470-2045(04)01610-9, 15522656.
7. Mocellin S, Semenzato G, Mandruzzato S, Rossi CR. Part II: Vaccines for haematological malignant disorders. The Lancet Oncology 2004, 5:727-37. 10.1016/S1470-2045(04)01649-3, 15581544.
8. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009, 21:346-351. 10.1016/j.coi.2009.05.016, 19500964.
9. Bansal GP, Malaspina A, Flores J. Future paths for HIV vaccine research: Exploiting results from recent clinical trials and current scientific advances. Curr Opin Mol Ther 2010, 12:39-46.
10. Benmira S, Bhattacharya V, Schmid ML. An effective HIV vaccine: a combination of humoral and cellular immunity?. Curr HIV Res 2010, 8:441-9. 10.2174/157016210793499286, 20636279.
11. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, Arthos J, Pal R, Markham P, Lu S. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008, 26:3947-3957. 10.1016/j.vaccine.2007.12.060, 18724414.
12. Kent S, De Rose R, Rollman E. Drug evaluation: DNA/MVA prime-boost HIV vaccine. Curr Opin Investig Drugs 2007, 8:159-167.
13. Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther 2010, 17:295-304. 10.1038/gt.2009.148, 19907498.
14. Truckenmiller ME, Norbury CC. Viral vectors for inducing CD8+ T cell responses. Expert Opin Biol Ther 2004, 4:861-868. 10.1517/14712598.4.6.861, 15174968.
15. Liu MA. Gene-based vaccines: recent developments. Curr Opin Mol Ther 2010, 12:86-93.
16. Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin 2008, 4:449-452.
17. Bot A, Stan AC, Inaba K, Steinman R, Bona C. Dendritic cells at a DNA vaccination site express the encoded influenza nucleoprotein and prime MHC class I-restricted cytolytic lymphocytes upon adoptive transfer. Int Immunol 2000, 12:825-832. 10.1093/intimm/12.6.825, 10837410.
18. Webster RG, Robinson HL. DNA vaccines: a review of developments. BioDrugs 1997, 8:273-292. 10.2165/00063030-199708040-00004, 18020519.
19. Maloy KJ, Erdmann I, Basch V, Sierro S, Kramps TA, Zinkernagel RM, Oehen S, Kündig TM. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001, 98:3299-3303. 10.1073/pnas.051630798, 30648, 11248073.
20. Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 2008, 31:215-223. 10.1097/CJI.0b013e3181611420, 18481391.
21. Bodles-Brakhop AM, Heller R, Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 2009, 17:585-592. 10.1038/mt.2009.5, 2835112, 19223870.
22. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006, 350:34-47. 10.1016/j.virol.2006.02.032, 16616287.
23. Lu Y, Ouyang K, Fang J, Zhang H, Wu G, Ma Y, Zhang Y, Hu X, Jin L, Cao R, Fan H, Li T, Liu J. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope. Vaccine 2009, 27:5411-5418. 10.1016/j.vaccine.2009.06.089, 19616501.
24. Bot A, Bot S, Garcia-Sastre A, Bona C. DNA immunization of newborn mice with a plasmid-expressing nucleoprotein of influenza virus. Viral Immunol 1996, 9:207-210. 10.1089/vim.1996.9.207, 8978016.
25. Skinner MA, Wedlock DN, de Lisle GW, Cooke MM, Tascon RE, Ferraz JC, Lowrie DB, Vordermeier HM, Hewinson RG, Buddle BM. The order of prime-boost vaccination of neonatal calves with Mycobacterium bovis BCG and a DNA vaccine encoding mycobacterial proteins Hsp65, Hsp70, and Apa is not critical for enhancing protection against bovine tuberculosis. Infect Immun 2005, 73:4441-4444. 10.1128/IAI.73.7.4441-4444.2005, 1168609, 15972546.
26. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, Robinson HL. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74. 10.1126/science.1058915, 11393868.
27. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998, 72:10180-10188. 110562, 9811759.
28. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331-335. 10.1038/415331a, 11797011.
29. Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH, Economou JS. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001, 61:8782-8786.
30. Egan MA, Chong SY, Megati S, Montefiori DC, Rose NF, Boyer JD, Sidhu MK, Quiroz J, Rosati M, Schadeck EB, Pavlakis GN, Weiner DB, Rose JK, Israel ZR, Udem SA, Eldridge JH. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 2005, 21:629-643. 10.1089/aid.2005.21.629, 16060834.
31. Biswas S, Reddy GS, Srinivasan VA, Rangarajan PN. Preexposure efficacy of a novel combination DNA and inactivated rabies virus vaccine. Hum Gene Ther 2001, 12:1917-1922. 10.1089/104303401753153965, 11589833.
32. Wang S, Parker C, Taaffe J, Solórzano A, García-Sastre A, Lu S. Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 2008, 26:3626-3633. 10.1016/j.vaccine.2008.04.073, 2802517, 18538900.
33. Bansal A, Jackson B, West K, Wang S, Lu S, Kennedy JS, Goepfert PA. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 2008, 82:6458-6469. 10.1128/JVI.00068-08, 2447094, 18448544.
34. Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008, 205:63-77. 10.1084/jem.20071331, 2234371, 18195071.
35. Todorova K, Ignatova I, Tchakarov S, Altankova I, Zoubak S, Kyurkchiev S, Mincheff M. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immun 2005, 5:1.
36. Dangoor A, Lorigan P, Keilholz U, Schadendorf D, Harris A, Ottensmeier C, Smyth J, Hoffmann K, Anderson R, Cripps M, Schneider J, Hawkins R. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother 2010, 59:863-873. 10.1007/s00262-009-0811-7, 20043222.
37. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003, 9:729-735. 10.1038/nm881, 12766765.
38. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7:790-802. 10.1038/nri2173, 17853902.
39. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, Hill AV. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005, 174:449-55.
40. Smith KA, Tam VL, Wong RM, Pagarigan RR, Meisenburg BL, Joea DK, Liu X, Sanders C, Diamond D, Kündig TM, Qiu Z, Bot A. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine 2009, 27:2603-2615. 10.1016/j.vaccine.2009.02.038, 19428867.
41. von Beust BR, Johansen P, Smith KA, Bot A, Storni T, Kündig TM. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur J Immunol 2005, 35:1869-1876. 10.1002/eji.200526124, 15909311.
42. Smith KA, Qiu Z, Wong R, Tam VL, Tam BL, Joea DK, Quach A, Liu X, Pold M, Malyankar UM, Bot A. Multivalent immunity targeting tumor associated antigens by intra-lymph node DNA-prime, peptide boost vaccination. Cancer Gene Therapy 2010,
43. Halwani R, Boyer JD, Yassine-Diab B, Haddad EK, Robinson TM, Kumar S, Parkinson R, Wu L, Sidhu MK, Phillipson-Weiner R, Pavlakis GN, Felber BK, Lewis MG, Shen A, Siliciano RF, Weiner DB, Sekaly RP. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol 2008, 180:7969-79.
44. Velu V, Kannanganat S, Ibegbu C, Chennareddi L, Villinger F, Freeman GJ, Ahmed R, Amara RR. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol 2007, 81:5819-28. 10.1128/JVI.00024-07, 1900286, 17376899.
45. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992, 11:3887-3895. 556898, 1396582.
46. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, Drake CG. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007, 117:3383-3392. 10.1172/JCI31184, 2000807, 17932562.
47. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006, 18:206-213. 10.1016/j.coi.2006.01.011, 16464564.
48. Wong RM, Smith KA, Tam VL, Pagarigan RR, Meisenburg BL, Quach AM, Carrillo MA, Qiu Z, Bot AI. TLR-9 signaling and TCR stimulation co-regulate CD8(+) T cell-associated PD-1 expression. Immunol Lett 2009, 127:60-67. 10.1016/j.imlet.2009.09.002, 19751765.
49. Schwarz K, Storni T, Manolova V, Didierlaurent A, Sirard JC, Röthlisberger P, Bachmann MF. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol 2003, 33:1465-70. 10.1002/eji.200323919, 12778463.
50. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immuno Lett 2003, 85:85-95.
51. Wang L, Smith D, Bot S, Dellamary L, Bloom A, Bot A. Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J Clin Invest 2002, 110:1175-84. 150792, 12393853.
52. Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol 2007, 179:5064-70.
53. Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ, Hipkiss E, Vignali DA, Pardoll DM, Drake CG. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009, 182:6659-6669. 10.4049/jimmunol.0804211, 19454660.
54. Riley JL. PD-1 signaling in primary T cells. Immunol Rev 2009, 229:114-125. 10.1111/j.1600-065X.2009.00767.x, 19426218.
55. Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, Hill BJ, Noto A, Ancuta P, Peretz Y, Fonseca SG, Van Grevenynghe J, Boulassel MR, Bruneau J, Shoukry NH, Routy JP, Douek DC, Haddad EK, Sekaly RP. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med 2010, 16:452-459. 10.1038/nm.2106, 20208540.
56. Laouar A, Manocha M, Haridas V, Manjunath N. Concurrent generation of effector and central memory CD8 T cells during vaccinia virus infection. PLoS ONE 2008, 3:e4089. 10.1371/journal.pone.0004089, 2605255, 19116651.
57. Huster KM, Busch V, Schiemann M, Linkemann K, Kerksiek KM, Wagner H, Busch DH. Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. PNAS USA 2004, 101:5610-5. 10.1073/pnas.0308054101, 397444, 15044705.
58. Alexander-Miller MA. High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors. Immunol Res 2005, 31:13-24. 10.1385/IR:31:1:13, 15591619.
59. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, Asher TE, Samri A, Schnuriger A, Theodorou I, Costagliola D, Rouzioux C, Agut H, Marcelin AG, Douek D, Autran B, Appay V. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007, 204:2473-2485. 10.1084/jem.20070784, 2118466, 17893201.
60. Lasaro MO, Ertl HC. Targeting inhibitory pathways in cancer immunotherapy. Curr Opin Immunol 2010, 22:385-90. 10.1016/j.coi.2010.04.005, 20466529.
61. Bullock TN, Mullins DW, Engelhard VH. Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J Immunol 2003, 170:1822-1829.
62. Bullock TN, Colella TA, Engelhard VH. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J Immunol 2000, 164:2354-2361.
63. Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu Y, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy 2009, 11:1-11.
64. Johansen P, Storni T, Rettig L, Qiu Z, Der-Sarkissian A, Smith KA, Manolova V, Lang KS, Senti G, Müllhaupt B, Gerlach T, Speck RF, Bot A, Kündig TM. Antigen kinetics determines immune reactivity. Proc Natl Acad Sci USA 2008, 105:5189-5194. 10.1073/pnas.0706296105, 2278203, 18362362.
65. Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. J Immunol 2005, 174:6292-6298.
66. van den Berg JH, Nuijen B, Beijnen JH, Vincent A, Tinteren H, Kluge J, Woerdeman LA, Hennink WE, Storm G, Schumacher TN, Haanen JB. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum gene ther 2009, 20:181-9. 10.1089/hum.2008.073, 2855251, 19301471.